The evidence indicates while the overall effect on MACE was not significant in CHD patients, the new immunomodulatory drugs could reduced incidence of angina, revascularization, IL-6 levels, neutrophil count levels, and improve the LVEF. The gene discussed is IL6; the disease is coronary artery disorder.